bivalirudin monotherapy

Related by string. * Bivalirudin : Angiomax bivalirudin . bivalirudin alone . R bivalirudin . bivalirudin / Monotherapy : methotrexate monotherapy . artemisinin monotherapy . Lucentis monotherapy . REMICADE monotherapy . Tysabri monotherapy . metformin monotherapy . infliximab monotherapy . Xeloda monotherapy . rituximab monotherapy . receiving Vectibix monotherapy * *

Related by context. All words. (Click for frequent words.) 74 unfractionated heparin UFH 71 Bivalirudin 70 plus glycoprotein IIb 68 plus GP IIb 67 lopinavir r arm 67 ischemia driven 67 tirofiban 66 Taxus Stent 66 oxycodone CR 65 Hypotension 65 p ≤ 65 mcg QD 65 candesartan cilexetil 65 DOXIL 65 binary restenosis 65 dose atorvastatin 65 XIENCE V PROMUS Stent 65 nadolol 65 IIIa inhibitor 65 mm Stent 65 Pegylated Liposomal Doxorubicin 65 -#.# ± [002] 64 aspirin clopidogrel 64 nicardipine 64 Hazard Ratio 64 mg BID dose 64 IIIa inhibitors 64 ertapenem 64 fluvastatin 64 abacavir lamivudine 64 FOLFOX4 64 lumbar spine bone 64 cTnI 64 Stent p = 64 dalteparin 64 Patency 64 Cypher Stent 64 lispro 64 receiving prophylactic anticoagulation 64 metastatic malignant 64 lumbar spine BMD 64 noninferior 64 reinfarction 64 Doxil ® 64 Double Blind Randomized 63 aspartate aminotransferase 63 iodixanol 63 p = NS 63 rizatriptan 63 idraparinux 63 abacavir Ziagen 63 ARCOXIA 63 everolimus eluting stent 63 aspartate aminotransferase AST 63 renal artery stenting 63 LV dysfunction 63 Prospective Randomized Trial 63 Nebulized 63 TPV r 63 atorvastatin #mg 63 FluCAM arm 63 tamsulosin 63 HOMA IR 63 sirolimus eluting stent 63 Pioglitazone 63 tipranavir r 63 CIMZIA TM certolizumab pegol 63 Myocardial Infarction Study 63 Kaplan Meier analysis 63 Oral Fingolimod 62 comparator arm 62 pooled comparator 62 nondiabetic patients 62 REYATAZ r arm 62 % Confidence Interval 62 Postoperative 62 symptomatic VTE 62 thromboembolism 62 HBeAg negative patients 62 Adjunctive 62 uncoated stent 62 TAXUS Express Stent 62 TAXUS p value 62 unfractionated heparin 62 melphalan prednisone 62 malignancy HCM 62 Ejection Fraction 62 tapentadol IR 62 Hazard Ratio HR 62 ^ sup #m 62 ezetimibe simvastatin 62 fondaparinux 62 sirolimus stent 62 Lenalidomide 62 bivalirudin 62 Thrombolysis 62 SUVmax 62 deep venous thromboses 62 unstable angina pectoris 62 lopinavir r 62 TLUS 62 oral diclofenac 62 imipramine Tofranil 62 TAXUS Liberte Long 62 GP IIb IIIa inhibitors 62 Percutaneous Tibial Nerve Stimulation 62 plus dexamethasone 62 alanine aminotransferase 62 NMIBC 62 eplerenone 62 sirolimus eluting 62 sirolimus eluting stents 62 confidence interval #.#-#.# 62 bivalirudin alone 62 nonfatal myocardial infarction MI 62 CANCIDAS 62 zonisamide SR 62 ULORIC 61 Mg Uk 61 ARIXTRA 61 Posaconazole 61 Angiographic 61 xanthine oxidase inhibitor 61 arterial thromboembolic events 61 Operative mortality 61 QTcF 61 See CLINICAL PHARMACOLOGY 61 primary patency 61 Mg Usa 61 argatroban 61 Pemetrexed 61 β blockers 61 GP IIb IIIa inhibitor 61 myocardial reperfusion 61 events MACE 61 placebo dexamethasone 61 Xalatan R 61 Myocardial Infarction TIMI 61 XELOX 61 everolimus eluting stents 61 Hycamtin ® 61 Pain Intensity 61 PREZISTA r arm 61 5-FU/LV 61 splenectomized 61 percutaneous vertebroplasty 61 rosuvastatin #mg 61 morphometric vertebral fractures 61 collagenous colitis 61 glycoprotein IIb IIIa inhibitor 61 Index CDAI 61 mg clopidogrel 61 rFSH 61 fosamprenavir 61 colorectal adenoma 61 -#.# log# 61 VELCADE melphalan 61 Sirolimus eluting 61 log# copies mL 61 biochemical relapse 61 clodronate 61 Score IPSS 61 creatinine ratio 61 #Gy 61 MR Angiography 61 Capecitabine 61 statistical significance p 61 statistically significant p = 61 Stent thrombosis 61 reteplase 61 efavirenz EFV 61 ug kg 61 #.#mg/dL 61 pretest probability 61 chlorambucil 61 pulmonary angiography 61 ARB telmisartan 61 pioglitazone HCl 61 ^ Tc 61 carotid artery stenting CAS 61 Non Responders 61 plus prednisone 61 adjunctive placebo 61 Stomatitis 60 μmol L 60 Ziprasidone 60 CYPHER Stent 60 multivariate Cox 60 leucopenia 60 pegylated liposomal doxorubicin 60 Interferon alfa 60 Crohn Disease Activity 60 acute cholecystitis 60 nonfatal myocardial infarction 60 Pred Forte 60 μg mL 60 carotid endarterectomy CEA 60 multivariable analysis 60 paclitaxel eluting stents 60 abciximab 60 coronary stenosis 60 TAXUS Stent 60 #mg BID [003] 60 aldosterone antagonist 60 Prolongs Survival 60 thromboembolic events 60 superficial femoral 60 CYPHER ® 60 P = .# 60 Renal dysfunction 60 MADRS score 60 ritonavir boosted 60 mycophenolate mofetil 60 RLAI 60 BUPHENYL R sodium phenylbutyrate 60 epoetin alpha 60 endarterectomy 60 bisoprolol 60 Median PFS 60 Score TOS 60 severe neutropenia 60 hematologic toxicity 60 quetiapine risperidone 60 SGPT 60 latanoprost 60 nadroparin 60 mcg BID 60 platelet inhibitor 60 p = ns 60 PEGylated anti 60 HBeAg 60 mL/min/#.# m 2 60 titrated glipizide 60 Engerix B 60 Prograf ® 60 EURIDIS 60 irbesartan 60 enalapril 60 rFVIIa 60 alfuzosin 60 periprocedural 60 ACR# ACR# 60 adriamycin 60 -#.# mg dL [001] 60 Flu Cy 60 -#.# log# copies mL 60 Carotid Artery Stenting 60 Hypercholesterolemia 60 cerebrovascular events 60 gemcitabine cisplatin 60 oxycodone IR 60 Exemestane 60 DES implantation 60 ALT elevation 60 chlorthalidone 60 BENICAR 60 Coronary Artery Bypass Graft 60 HBeAg seroconversion 60 fluticasone salmeterol 60 salmeterol fluticasone 60 Hyperlipidemia 60 AST ALT 60 recurrent DVT 60 tapentadol ER 60 fluorouracil leucovorin 60 β blocker 60 LPV r 60 urinary N telopeptide 60 Carotid 60 FOLFOX4 alone 60 Fracture Risk 60 Intravitreal 60 BMS p = 60 Neoadjuvant 60 gemcitabine carboplatin 60 adenoma recurrence 60 Platinol ® cisplatin 60 sorafenib Nexavar 60 receiving INTRON 60 chemoradiation therapy 60 Serum creatinine 60 Bare Metal Stent 60 somatostatin analog 60 STN stimulation 60 Fulvestrant 59 Visipaque 59 endoscopic ultrasonography 59 imipenem 59 ibandronate 59 extrapyramidal symptoms 59 Unstable Angina 59 doxazosin 59 haematologic 59 CI -#.# 59 Infarct 59 NAVISTAR R 59 biologic DMARD 59 epoprostenol 59 perioperative mortality 59 GPIIb IIIa inhibitors 59 receiving VICTRELIS 59 PEG IFN 59 NEVO TM 59 ADCS CGIC 59 non valvular atrial 59 cyclophosphamide methotrexate 59 NPH insulin 59 Eluting Stent 59 HMG CoA reductase inhibitor 59 Tiotropium 59 Coronary CTA 59 Computed tomographic 59 STRIDE PD 59 CIMZIA ™ 59 glycoprotein IIb IIIa inhibitors 59 PASI scores 59 SGOT 59 Non inferiority 59 AUC0 59 NEVO 59 MACCE 59 Intracranial 59 LNG IUS 59 Gastrointestinal Stromal Tumors 59 angiotensin converting enzyme inhibitors 59 ximelagatran 59 TAXUS Express2 Paclitaxel Eluting 59 mitomycin 59 Randomized Evaluation 59 interobserver 59 Lantus ® 59 Clinical Outcome 59 bronchoalveolar lavage 59 PaO 2 59 multivariable adjusted 59 hypophosphatemia 59 diameter stenosis 59 azacytidine 59 atazanavir ritonavir 59 Intravascular 59 Orthostatic Hypotension 59 Cypher Sirolimus 59 mmol kg 59 OPCAB 59 PRADAXA #mg 59 salmeterol fluticasone propionate 59 Platinol ® 59 Abciximab 59 undetectable HBV DNA 59 dacarbazine DTIC 59 myocardial necrosis 59 PREZISTA ritonavir 59 PSA nadir 59 zotarolimus eluting stent 59 CsA 59 mg p = 59 bypass graft CABG surgery 59 dose pravastatin 59 platelet reactivity 59 CT Angiography 59 TMP SMX 59 dual endothelin receptor antagonist 59 ketorolac 59 mg TID 59 Pharmacodynamics 59 ticlopidine 59 Target Lesion Revascularization TLR 59 TIMP 1 59 artery occlusion 59 death reinfarction 59 HES CEL 59 dose Iluvien 59 paricalcitol 59 ATACAND 59 adjunctive ABILIFY 59 #mg BID [001] 59 dose dexamethasone 59 racemic albuterol 59 invasive carcinomas 59 microvessel density 59 serum urate 59 desvenlafaxine succinate 59 International Prostate Symptom 59 parecoxib 59 ALVESCO 59 FOLPI 59 intima media thickness 59 lipid lowering agents 59 revascularizations 59 μg liter 59 Pharmacokinetics PK 59 ABC/3TC 59 Fasting blood glucose 59 serum triglycerides 59 intravenous diuretics 59 HbA 1c levels 59 doxorubicin docetaxel 59 symptomatic intracranial hemorrhage 59 myocardial viability 59 interferon alfa 2b 59 Hemodynamic 59 peripheral sensory neuropathy 59 Warfarin Coumadin 59 elevated creatinine 59 uM 59 Epirubicin 59 nonfatal MI 59 μg kg 59 postoperative complication 59 Severity MSCS score 59 XIENCE V demonstrated 59 symptomatic intracranial 59 LVEF 59 Acute Decompensated Heart Failure 59 MCyR 59 mg qd 59 serum estradiol 59 RECIST Response Evaluation Criteria 59 Histologic 59 mIU ml 59 echocardiographic parameters 59 steroid dexamethasone 59 CYPHER R Sirolimus eluting 59 response CCyR 59 TAXOTERE R 59 atheroma volume 59 achieved CCyR 59 pulmonary capillary wedge 59 r2 = 59 albumin excretion rate 59 Chemoradiation 59 troponin T 59 teriflunomide 59 tenecteplase 59 Acute Coronary Syndromes 59 pericardial effusion 59 μg L 59 antiplatelet agent 59 leukocyte count 59 Rating Scale BPRS 59 transcranial Doppler ultrasound 59 Peripheral Arterial 59 mmHg diastolic 59 Events MACE 59 IOP lowering 58 Castration Resistant Prostate Cancer 58 hemoglobin Hb 58 uricase 58 ‰ ¥ 58 pamidronate 58 generalized edema 58 transurethral resection 58 variceal hemorrhage 58 Interferon beta 1a 58 liver histology 58 angiographically 58 radial artery grafts 58 Clopidogrel 58 Pharmacodynamic 58 stage IIIb IV 58 FLOMAX 58 confidence intervals CIs 58 CIMZIA TM 58 preoperative PSA 58 beta 1a 58 postprocedure 58 dacarbazine 58 hemodynamically significant 58 placebo p = 58 certolizumab 58 eptifibatide 58 Acute Myocardial Infarction 58 Carvedilol 58 Elitek 58 % CI #.#-#.# [007] 58 definite stent thrombosis 58 Benign Prostatic Hyperplasia 58 platelet inhibition 58 methotrexate monotherapy 58 Proteinuria 58 Fractional Flow Reserve 58 mg/m2 dose 58 Brain Metastases 58 serum prostate 58 oral Hycamtin 58 NIHSS 58 Coronary artery bypass grafting 58 Kidney Function 58 ATV RTV 58 Zometa hazard 58 phonophobia 58 CCyR 58 reflux esophagitis 58 4mg/kg 58 LV ejection fraction 58 T2 lesion volume 58 Catheter Ablation 58 ara C 58 zotarolimus 58 mcg kg REBETOL 58 baseline LDH 58 cytopenias 58 Navelbine 58 Rating Scale MADRS 58 transthoracic 58 lumiracoxib 58 SVR# 58 #mg #mg #mg [003] 58 Betaferon R 58 nmol liter 58 sitaxsentan 58 graft occlusion 58 grade squamous intraepithelial 58 daunorubicin 58 Transesophageal 58 fibrinolytic 58 thickness IMT 58 darbepoetin alfa 58 dopamine partial agonist 58 Pharmacokinetic parameters 58 ACR# responses 58 analgesic efficacy 58 Androgel R 58 eluting stent 58 budesonide pMDI 58 fatigue asthenia 58 Am J Cardiol 58 CONTRAINDICATIONS 58 Mean Symptom Complex 58 discontinuations due 58 TM Everolimus Eluting 58 #F FDG 58 amoxicillin clavulanate 58 trimethoprim sulfamethoxazole 58 FOLFOX6 58 Ann Intern Med 58 femoral neck BMD 58 Percutaneous Coronary Intervention 58 Cardiotoxicity 58 enoxaparin 58 Echocardiographic 58 ZACTIMA 58 carotid stenosis 58 alanine transaminase 58 moderate renal impairment 58 Predictive Value 58 transurethral 58 radiotherapy RT 58 histological subtype 58 MIC# [001] 58 pegylated interferon alfa 2b 58 spine BMD 58 fluoropyrimidine 58 estramustine 58 glulisine 58 Carotid Endarterectomy 58 relapsed MM 58 QTc prolongation 58 flutamide 58 VAPRISOL 58 univariate 58 Cystatin C 58 Endarterectomy 58 cilostazol 58 PROMUS 58 doxorubicin cyclophosphamide 58 Coronary artery bypass graft 58 EDEMA3 58 #.#/#.# mm Hg [003] 58 drotrecogin alfa activated 58 annualized relapse 58 ß blockers 58 ABVD 58 FASLODEX 58 p = #.# [003] 58 plus gemcitabine 58 MBq 58 hsCRP levels 58 #.#g/day 58 creatinine clearance 58 interferon alfa 2a 58 % CI #.#-#.# [008] 58 mg hydrochlorothiazide 58 Acetate Rectal Suppositories 58 serum magnesium 58 unstable angina UA 58 clinically meaningful reductions 58 Subgroup analysis 58 Autologous Stem Cell Transplantation 58 Albuminuria 58 FDG PET imaging 58 cinacalcet 58 FDG-PET/CT 58 atrioventricular block 58 left ventricular systolic 58 timolol 58 #.#-#.# p = 58 fluticasone propionate FP 58 Papillary 58 conjunctival hyperemia 58 intracoronary 58 log# IU mL 58 aminotransferases 58 octreotide LAR 58 #mg doses [002] 58 #μg [001] 58 Transurethral 58 Prospective Randomized 58 ritonavir boosted atazanavir 58 Stent Thrombosis 58 TAXUS Express2 58 rs# [002] 58 HBeAg positive patients 58 hip BMD 58 intravesical therapy 58 angiotensin converting enzyme inhibitor 58 gefitinib Iressa 58 CK MB 58 Sirolimus eluting Coronary Stent 58 angiotensin II receptor blockers 58 cGy 58 ReoPro 58 nimodipine 58 pT2 58 divalproex sodium 58 Erlotinib 58 x ULN 58 Pelvic Organ Prolapse 58 Thal Dex 58 FOLFIRI 58 p = .# [001] 58 neutropenia dehydration dyspnea 58 mEq 58 subtrochanteric 58 Contraindications 57 MIRAPEX 57 Pharmacokinetic 57 thrombocytopenic 57 carotid artery stenosis 57 TAXUS Element Stent 57 ribavirin RBV 57 carotid IMT 57 Response Evaluation Criteria 57 Lamotrigine 57 Percutaneous Transluminal Coronary Angioplasty 57 glomerular filtration rate 57 oblimersen 57 PSADT 57 Statistically Significant 57 micafungin 57 Platelet Aggregation 57 recurrent venous thromboembolism 57 TRUS 57 PRADAXA 57 PEY 57 antiarrhythmic 57 regression coefficient 57 tacrolimus ointment 57 TAXUS ® 57 infliximab monotherapy 57 interobserver reliability 57 ß = 57 transaminase elevations 57 Lovaza ® 57 -#.# mg dL [002] 57 Prognostic Value 57 microg 57 interstitial brachytherapy 57 Peg IFN 57 metastatic GIST 57 mCi 57 urine NGAL 57 Ranolazine 57 primary percutaneous coronary 57 myocardial infarction ventricular fibrillation 57 urate lowering therapy 57 dose cytarabine 57 postoperative mortality 57 sensitivity specificity 57 low dose dexamethasone 57 PROMUS ® 57 Febrile neutropenia 57 oral allopurinol 57 alpha 2a 57 Atomoxetine 57 Troponin T 57 Endothelial Function 57 angiographic restenosis 57 Acute Ischemic Stroke 57 plus medroxyprogesterone acetate 57 rt PA 57 fluorouracil 57 neointimal hyperplasia 57 leukopenia 57 complete cytogenetic response 57 simvastatin #mg 57 Vertebral 57 EQUETRO 57 Apidra ® 57 mU liter 57 Navelbine ® 57 Somnolence 57 logistic regression analysis 57 foveal thickness 57 statistically significant p 57 cardiac resynchronisation therapy 57 #mg/day [001] 57 lanthanum carbonate 57 alanine aminotransferase ALT 57 #mmHg [001] 57 locoregional recurrence 57 infarct size 57 #.#/#.# mmHg [001] 57 serum creatinine levels 57 carboplatin paclitaxel 57 olmesartan medoxomil hydrochlorothiazide 57 TMC# r 57 reactive hyperemia 57 8mg/kg 57 tigecycline 57 brand ciclesonide HFA 57 insulin detemir 57 TURBT 57 GORE TAG Device 57 % CI #.#-#.# [003] 57 invasive aspergillosis 57 histologic subtype 57 esomeprazole 57 fraction LVEF 57 deoxy 57 prolonged QT interval 57 oxcarbazepine 57 prostate TURP 57 glimepiride 57 Skin sterol 57 Telmisartan 57 CHAMPION PCI 57 plasma creatinine 57 Myelodysplastic Syndrome MDS 57 esophageal varices 57 Antiviral Therapy 57 Postoperative complications 57 IM progesterone 57 FluCAM 57 VerifyNow 57 P ≤ 57 mesilate 57 tolvaptan 57 neutropaenia 57 nausea photophobia 57 TGZ 57 statin monotherapy 57 Atrial 57 pmol L 57 Major Adverse Cardiac 57 Anti Bacterial Envelope 57 Taxol ® 57 Stenting Trial 57 drug eluting stent implantation 57 CLINICAL PHARMACOLOGY 57 FDA defined valvulopathy 57 antibiotics metronidazole 57 Tasigna prolongs 57 perioperatively 57 pT3 57 Soft Tissue Sarcoma 57 angiographic outcomes 57 interquartile range IQR 57 plasma kallikrein inhibitor 57 intima media thickness IMT 57 recurrent VTE 57 ACTEMRA TM 57 serum urate levels 57 active comparator 57 HRCT 57 CR nPR 57 composite endpoint 57 serum cortisol 57 dexmedetomidine 57 Ischemic 57 pg ml 57 hepatorenal syndrome 57 boosted protease inhibitor 57 cardiac perfusion 57 Partial Response 57 decitabine 57 icatibant 57 D dimer 57 lamotrigine 57 patients undergoing CABG 57 MDRD 57 GG genotype 57 achieved ACR# 57 postintervention 57 dimeglumine 57 beclomethasone dipropionate 57 ST Segment Elevation 57 Non Alcoholic Steatohepatitis 57 Renal Insufficiency 57 pulsatile flow 57 elevated LDH 57 SGRQ 57 rebleeding 57 glomerular filtration 57 NNT = 57 mg ustekinumab 57 TIMI 57 myocardial infarction stroke 57 conjugated equine estrogens 57 ADAS cog 57 q#h 57 concurrent chemoradiation 57 TC HDL 57 CI #.#-#.# [002] 57 VT VF 57 mineral density BMD 57 p = .# [002] 57 carcinoembryonic antigen 57 Platinol 57 nephrotoxicity 57 elevated troponin 57 brimonidine 57 artery stenosis 57 workhorse lesions 57 prednisone prednisolone plus 57 aortic insufficiency 57 hematological parameters 57 systemic embolism 57 contrast induced nephropathy 57 stent restenosis 57 DAS# CRP 57 gadobutrol 57 nodular partial response 57 mg m² 57 PROMUS TM 57 sumatriptan naproxen sodium 57 randomized multicenter trial 57 #.#mg/kg [002] 57 AneuRx 57 lipoprotein Lp 57 Showed Significant 57 antiarrhythmic drug 57 NEVO ™ 57 Left Ventricular 57 insulin glulisine 57 mg QD 57 Nesiritide 57 lactate dehydrogenase LDH 57 severe exacerbations 57 gadolinium enhancing lesions 57 Sustained virologic response 57 lymphocyte count 56 DJI #.# 56 Scale PANSS 56 REMINYL ® 56 posttreatment 56 Prostate Cancer Recurrence 56 XIENCE V stent 56 thrombus aspiration 56 endoscopic remission 56 Myocardial 56 piperacillin tazobactam 56 baseline HbA1c 56 mcg ml 56 Figure 1A 56 Endocrine Therapy 56 amisulpride 56 TAVR 56 Cmax 56 Treatment Outcome 56 low dose Iluvien 56 fractional shortening 56 Quantitation 56 periprocedural MI 56 Visual Analog Scale 56 serum HBV DNA 56 ASTEROID 56 paresthesias 56 alteplase 56 ritonavir boosted lopinavir 56 non splenectomized 56 Fasting plasma glucose 56 QVAR R 56 NYHA functional class 56 Preoperative 56 ADHD Rating Scale 56 elective PCI 56 tenofovir emtricitabine 56 baseline FEV 56 Vascular Stent 56 tolterodine ER 56 ipsilateral stroke 56 Diabetic Neuropathy 56 triglyceride TG 56 mmHg p = 56 transcranial Doppler 56 HCV Genotype 56 Stenting 56 paclitaxel carboplatin 56 laboratory abnormalities 56 PROMUS Element 56 Poisson regression 56 DAS# remission 56 thromboembolic complications 56 glutamyl 56 mcg mL 56 percutaneous transluminal coronary angioplasty 56 Secondary endpoints included 56 advanced adenomas 56 Cinacalcet 56 irinotecan cisplatin 56 neuropathy sensory 56 baseline Hb 56 occlusive disease 56 cardiac repolarization 56 odds ratios ORs 56 colorectal liver metastases 56 Carotid Revascularization Endarterectomy vs. 56 Ann Oncol 56 QTc 56 DUROS 56 Orally Active 56 corrected QT interval 56 V Everolimus Eluting Coronary 56 clopidogrel Plavix 56 plasma cortisol 56 amprenavir 56 C Reactive Protein 56 QD dosing 56 #OHD 56 linaclotide treated 56 simvastatin ezetimibe 56 ASCUS 56 Diseases Ninth 56 ACR# response 56 lactate dehydrogenase 56 plasma renin activity 56 achieved statistical significance 56 tumor xenograft models 56 Invasive Breast Cancer 56 intravenous dosing 56 mg subcutaneous 56 saline placebo 56 Sanofi Aventis Taxotere 56 underwent surgical resection 56 stent stenosis 56 prucalopride 56 inotropic agents 56 FXIII 56 Humate P 56 tobramycin inhalation solution 56 ug dose 56 leiomyomas 56 CABG coronary artery 56 Endometrial 56 interobserver agreement 56 Scale cognitive subscale 56 Bioavailability 56 thrombolytics 56 pharmacologically active isomer 56 Randomised 56 #mg/m# [001] 56 pegylated interferon alfa 56 aPTT 56 postoperative chemotherapy 56 mild renal insufficiency 56 pCR 56 Risk Stratification 56 -#.# mmol L 56 Spinal Cord Stimulation 56 nmol 56 IFN beta 56 interferon alfa 56 crossclamp 56 inhaled budesonide 56 EQ 5D 56 segment binary restenosis 56 TEAEs 56 NEXIUM 56 mg Proellex 56 Schizophrenia Treatment 56 aminotransferase ALT 56 urine albumin 56 SpO 2 56 plus COPEGUS 56 bi ventricular pacing 56 Melphalan 56 ExTRACT TIMI 56 mcg kg 56 univariate analysis 56 3mg/kg 56 tamoxifen Nolvadex ® 56 recurrent glioblastoma multiforme 56 Univariate 56 TAXUS Liberté stent 56 heparin induced thrombocytopenia 56 oncologic outcomes 56 Emboli Capture Guidewire 56 Kaplan Meier estimates

Back to home page